<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3277">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02043301</url>
  </required_header>
  <id_info>
    <org_study_id>B1481024</org_study_id>
    <nct_id>NCT02043301</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics And Relative Bioavailability Of PF-04950615 When Administered To The Abdomen, Thigh Or Upper Arm</brief_title>
  <official_title>A Phase 1, Open-Label, Randomized, Single Dose, Parallel Group Study To Assess Injection Site Relative Bioavailability Of PF-04950615 Following Subcutaneous Administration In Adult Subjects With Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to characterize the single dose pharmacokinetics of PF-04950616 following
      subcutaneous injection to the abdomen, upper arm or the thigh.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - inf)]</measure>
    <time_frame>85 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - inf). It is obtained from AUC (0 - t) plus AUC (t - inf).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>85 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum observed plasma concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>85 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent SC Clearance (CL/F)</measure>
    <time_frame>85 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>A measure of the rate at which a drug substance is removed from blood divided by bioavailability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>85 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time to reach maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F)</measure>
    <time_frame>85 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>A theoretical volume in which the total amount of drug is uniformly distributed to produce the desired plasma concentration divided by bioavailability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Terminal Elimination Half-Life (t1/2)</measure>
    <time_frame>85 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time measured for the terminal plasma concentration to decrease by one half</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the LDL-C effect curve</measure>
    <time_frame>85 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the LDL-C effect curve from time 0 to the last timepoint with measurable effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum LDL-C lowering</measure>
    <time_frame>85 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum LDL-C lowering</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum LDL-C lowering</measure>
    <time_frame>85 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to reach the maximum LDL-C lowering</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Single 150 mg PF-04950615 dose administered to the abdomen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single 150 mg PF-04950615 dose administered to the upper arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single 150 mg PF-04950615 dose administered to the thigh</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PF-04950615</intervention_name>
    <description>Single 150 mg PF-04950615 dose administered SC to the abdomen</description>
    <arm_group_label>Single 150 mg PF-04950615 dose administered to the abdomen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-04950615</intervention_name>
    <description>Single 150 mg PF-04950615 dose administered SC to the upper arm</description>
    <arm_group_label>Single 150 mg PF-04950615 dose administered to the upper arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-04950615</intervention_name>
    <description>Single 150 mg PF-04950615 dose administered SC to the thigh</description>
    <arm_group_label>Single 150 mg PF-04950615 dose administered to the thigh</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects 18 to 65 years of age.

          -  Body Mass Index (BMI) â‰¤ 33 kg/m2, and total body weight of 60 kg to 90 kg (132 lbs to
             198 lbs).

          -  Fasting LDL-C must be &gt; 130 mg/dL (borderline high per NCEP ATP III criteria) at two
             qualifying visits: initial screening (Days -28 to -14) and Day -7.

        Exclusion Criteria:

          -  Poorly controlled type 1 or type 2 diabetes mellitus (HbA1c &gt; 9.0%).

          -  History of a cardiovascular or cerebrovascular event (eg, MI, stroke, TIA) or related
             procedure (eg, angioplasty) during the past year.

          -  Subjects who meet the New York Heart Association (NYHA) criteria for congestive heart
             failure (CHF) classes III or IV.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1481024&amp;StudyName=Pharmacokinetics%20And%20Relative%20Bioavailability%20Of%20PF-04950615%20When%20Administered%20To%20The%20Abdomen%2C%20Thigh%20Or%20Upper%20Arm</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>January 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>bioavailability</keyword>
  <keyword>PF-04950615</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
